463 related articles for article (PubMed ID: 35216137)
1. Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?
Repáraz D; Aparicio B; Llopiz D; Hervás-Stubbs S; Sarobe P
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216137
[TBL] [Abstract][Full Text] [Related]
2. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
Liu Z; Liu X; Liang J; Liu Y; Hou X; Zhang M; Li Y; Jiang X
Front Immunol; 2021; 12():765101. PubMed ID: 34675942
[TBL] [Abstract][Full Text] [Related]
4. Immune-based therapies for hepatocellular carcinoma.
Pinato DJ; Guerra N; Fessas P; Murphy R; Mineo T; Mauri FA; Mukherjee SK; Thursz M; Wong CN; Sharma R; Rimassa L
Oncogene; 2020 Apr; 39(18):3620-3637. PubMed ID: 32157213
[TBL] [Abstract][Full Text] [Related]
5. Perspectives of immunotherapy in hepatocellular carcinoma (HCC).
Büttner N; Schmidt N; Thimme R
Z Gastroenterol; 2016 Dec; 54(12):1334-1342. PubMed ID: 27936483
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for hepatocellular carcinoma.
Li S; Yang F; Ren X
Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
[TBL] [Abstract][Full Text] [Related]
7. Current status and perspectives of immune-based therapies for hepatocellular carcinoma.
Aerts M; Benteyn D; Van Vlierberghe H; Thielemans K; Reynaert H
World J Gastroenterol; 2016 Jan; 22(1):253-61. PubMed ID: 26755874
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic approaches for hepatocellular carcinoma.
Longo V; Gnoni A; Casadei Gardini A; Pisconti S; Licchetta A; Scartozzi M; Memeo R; Palmieri VO; Aprile G; Santini D; Nardulli P; Silvestris N; Brunetti O
Oncotarget; 2017 May; 8(20):33897-33910. PubMed ID: 28420805
[TBL] [Abstract][Full Text] [Related]
9.
Lurje I; Werner W; Mohr R; Roderburg C; Tacke F; Hammerich L
Front Immunol; 2021; 12():650486. PubMed ID: 34025657
[TBL] [Abstract][Full Text] [Related]
10. Potential of immunotherapy for hepatocellular carcinoma.
Breous E; Thimme R
J Hepatol; 2011 Apr; 54(4):830-4. PubMed ID: 21145836
[TBL] [Abstract][Full Text] [Related]
11. Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma.
Mohr R; Jost-Brinkmann F; Özdirik B; Lambrecht J; Hammerich L; Loosen SH; Luedde T; Demir M; Tacke F; Roderburg C
Front Immunol; 2021; 12():652172. PubMed ID: 33859646
[TBL] [Abstract][Full Text] [Related]
12. Engineering T cells for immunotherapy of primary human hepatocellular carcinoma.
Caraballo Galva LD; Cai L; Shao Y; He Y
J Genet Genomics; 2020 Jan; 47(1):1-15. PubMed ID: 32089500
[TBL] [Abstract][Full Text] [Related]
13. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
Oura K; Morishita A; Tani J; Masaki T
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
[TBL] [Abstract][Full Text] [Related]
14. Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy.
Schmidt N; Neumann-Haefelin C; Thimme R
Dig Dis; 2012; 30(5):483-91. PubMed ID: 23108304
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
Harding JJ; El Dika I; Abou-Alfa GK
Cancer; 2016 Feb; 122(3):367-77. PubMed ID: 26540029
[TBL] [Abstract][Full Text] [Related]
16. The yin and yang of evasion and immune activation in HCC.
Makarova-Rusher OV; Medina-Echeverz J; Duffy AG; Greten TF
J Hepatol; 2015 Jun; 62(6):1420-9. PubMed ID: 25733155
[TBL] [Abstract][Full Text] [Related]
17. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
Ding Z; Dong Z; Chen Z; Hong J; Yan L; Li H; Yao S; Yan Y; Yang Y; Yang C; Li T
Front Immunol; 2021; 12():733530. PubMed ID: 34659220
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for hepatocellular carcinoma: Current and future.
Johnston MP; Khakoo SI
World J Gastroenterol; 2019 Jun; 25(24):2977-2989. PubMed ID: 31293335
[TBL] [Abstract][Full Text] [Related]
19. Alpha fetoprotein is more than a hepatocellular cancer biomarker: from spontaneous immune response in cancer patients to the development of an AFP-based cancer vaccine.
Bei R; Mizejewski GJ
Curr Mol Med; 2011 Oct; 11(7):564-81. PubMed ID: 21707514
[TBL] [Abstract][Full Text] [Related]
20. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer.
Aparicio B; Repáraz D; Ruiz M; Llopiz D; Silva L; Vercher E; Theunissen P; Tamayo I; Smerdou C; Igea A; Santisteban M; Gónzalez-Deza C; Lasarte JJ; Hervás-Stubbs S; Sarobe P
Front Immunol; 2022; 13():985886. PubMed ID: 36405725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
